In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Navigating the Labyrinth of Regulation and Taking Drug Safety Reporting to the Next Level with Automation
An article published by Pharma focus, authored by ICON experts Arinder Sihota, PhD and Beata Kolon, on the challenges of global clinical trials in an ever-changing regulatory environment and the advantages of applying innovative automation to safety reporting.
-
Next generation of clinical trials
In this edition of Pharma Times, ICON's Tom O’Leary contributes to the discussion on the next generation of clinical trials in particular participant engagement, expansive data and the use of digital technology for patients and pharma.
-
Special Report on Immunology & Autoimmunity: Turn of the coin
A Drug Discovery News (DDN) article featuring commentary from Marco Silleni, discussing the challenges of autoimmune disorders. Silleni mentions the potential for extended therapy often means that regulatory authorities are much more focused on chronic toxicities and the requirement of long-term safety data. In addition, chronic autoimmunity diseases often mean lengthy trials and clinical monitoring, therefore the qualifications and skills of assessors are paramount.
-
Immunotherapy Combination Trials Q&A
Q&A article published by Pharmaceutical Market Europe (PME) featuring Chris Learn and Martin Lachs, discussing how best to achieve success in an increasingly crowded and competitive immuno-oncology field, where the rapid evolution of trial design has occurred as a competitive necessity.
-
ICON Introduces New Drug Safety Reporting Solution
An Outsourcing Pharma article featuring commentary from Quintin Van Wyk on ICON’s new drug safety reporting platform. Launched at DIA Europe, the platform automates complex processes to ensure compliance in an ever-changing regulatory space.
-
Adopting a Strategy to Identify Highest Commercial Value Products
A thought leadership article written by Vicki Anastasi, published by the Journal of Medical Device Regulation (JMDR), exploring the challenges of transitioning to the new EU Medical Devices Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) and advising manufactures on how to prioritise their product portfolio to ensure a smooth transition.
-
A Primer for Manufacturers Adjusting to Value-Based Healthcare
A thought leadership article published by MPO Magazine, written by ICON expert Vicki Anastasi, on the challenges of a value-based healthcare market and the importance of demonstrating clinical efficacy and cost impact of new devices. The piece discusses how partnering with an experienced CRO with a track record in clinical evidence generation, economic modelling, and commercialisation can help devices to achieve strong market impact.
-
ICON Rolls Out Digital Platform Developed with Dimension Data
An article published by Fierce Biotech on ICON’s new digital platform developed with Dimension Data. The innovative platform supports digital trials and patient interaction by reducing complexity and cost to ultimately enhance the efficiency and productivity of client pipelines.
-
Improving Pharma R&D Efficiency
With development cycles becoming too long, trial complexity increasing, and greater scrutiny of the economic value of new treatments, pharma R&D business models are under significant pressures to improve R&D efficiency. In an ICON industry survey of pharmaceutical executives and professionals on Pharma R&D Efficiency, the challenges most frequently cited are explored. Learn more in this Applied Clinical Trials Industry Trends 2019 article.
-
Parkinson’s Disease Clinical Trials
An Outsourcing-Pharma (OSP) article exploring Parkinson’s disease clinical trials, featuring commentary from ICON Central Nervous System (CNS) experts Dr Peter Schueler (Sr VP, Drug Development Services) and Haichen Yang (VP, Global Therapeutic Lead). For neurological research areas, digital endpoints may soon be used as primary endpoints, allowing for in-home trials to be conducted over longer periods of time.
